131 related articles for article (PubMed ID: 38895100)
1. Usefulness of health checkup-based indices in identifying metabolic dysfunction-associated steatotic liver disease.
Miwa T; Tajirika S; Imamura N; Adachi M; Horita R; Hanai T; Ng CH; Siddiqui MS; Fukao T; Shimizu M; Yamamoto M
JGH Open; 2024 Jun; 8(6):e13110. PubMed ID: 38895100
[TBL] [Abstract][Full Text] [Related]
2. Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men.
Crudele L; De Matteis C; Novielli F; Di Buduo E; Petruzzelli S; De Giorgi A; Antonica G; Berardi E; Moschetta A
Biol Sex Differ; 2024 May; 15(1):43. PubMed ID: 38760802
[TBL] [Abstract][Full Text] [Related]
3. Associations between serum ferritin baselines and trajectories and the incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.
Song Z; Miao X; Xie X; Tang G; Deng J; Hu M; Liu S; Leng S
Lipids Health Dis; 2024 May; 23(1):141. PubMed ID: 38760825
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive Indices of MASLD Are Associated With Hypogonadism in Male Patients With Type 2 Diabetes Mellitus.
Caretta N; Scafa R; Graziani A; Crepaldi MC; Vedovato M; Avogaro A; Ferlin A
J Clin Endocrinol Metab; 2024 Jan; 109(2):e522-e530. PubMed ID: 37795977
[TBL] [Abstract][Full Text] [Related]
5. Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes.
Della Pepa G; Lupoli R; Masulli M; Boccia R; De Angelis R; Gianfrancesco S; Piccolo R; Rainone C; Rivellese AA; Annuzzi G; Bozzetto L
J Endocrinol Invest; 2024 Mar; ():. PubMed ID: 38498227
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive assessment of hepatic steatosis by ultrasound-derived fat fraction in individuals at high-risk for metabolic dysfunction-associated steatotic liver disease.
Tavaglione F; Flagiello V; Terracciani F; Gallo P; Capparelli E; Spiezia C; De Vincentis A; Palermo A; Scriccia S; Galati G; Napoli N; Daniels SJ; Blau JE; Carlsson B; Khazrai YM; Incalzi RA; Picardi A; Vespasiani-Gentilucci U
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3787. PubMed ID: 38461408
[TBL] [Abstract][Full Text] [Related]
7. Bioelectrical impedance parameters add incremental value to waist-to-hip ratio for prediction of metabolic dysfunction associated steatotic liver disease in youth with overweight and obesity.
Song K; Seol EG; Yang H; Jeon S; Shin HJ; Chae HW; Kim EK; Kwon YJ; Lee JW
Front Endocrinol (Lausanne); 2024; 15():1385002. PubMed ID: 38883602
[TBL] [Abstract][Full Text] [Related]
8. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
[TBL] [Abstract][Full Text] [Related]
9. Association between the composite dietary antioxidant index and metabolic dysfunction-associated steatotic liver disease in adults: a cross-sectional study from NHANES 2017-2020.
Yang Z; Song S; Li L; Yuan Z; Li Y
Sci Rep; 2024 Jun; 14(1):13801. PubMed ID: 38877074
[TBL] [Abstract][Full Text] [Related]
10. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
[TBL] [Abstract][Full Text] [Related]
11. Non-linear association between long-term air pollution exposure and risk of metabolic dysfunction-associated steatotic liver disease.
Cheng WC; Wong PY; Wu CD; Cheng PN; Lee PC; Li CY
Environ Health Prev Med; 2024; 29():7. PubMed ID: 38346730
[TBL] [Abstract][Full Text] [Related]
12. Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease.
Min Y; Wei X; Wei Z; Song G; Zhao X; Lei Y
Cardiovasc Diabetol; 2024 Jun; 23(1):188. PubMed ID: 38824550
[TBL] [Abstract][Full Text] [Related]
13. Metabolic dysfunction-associated steatotic liver disease and risk of esophageal cancer in patients with diabetes mellitus: a nationwide cohort study.
Jeon YJ; Han K; Lee SW; Lee JE; Park J; Cho IY; Cho JH; Shin DW
Dis Esophagus; 2024 Apr; ():. PubMed ID: 38587429
[TBL] [Abstract][Full Text] [Related]
14. Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes.
Sviklāne L; Olmane E; Dzērve Z; Kupčs K; Pīrāgs V; Sokolovska J
J Gastroenterol Hepatol; 2018 Jan; 33(1):270-276. PubMed ID: 28464337
[TBL] [Abstract][Full Text] [Related]
15. Alanine aminotransferase cutoffs for the pediatric fatty liver disease: Major impact of the reference population.
Aitokari L; Lahti S; Kivelä L; Riekki H; Hiltunen P; Vuorela N; Viitasalo A; Soininen S; Huhtala H; Lakka T; Kurppa K
J Pediatr Gastroenterol Nutr; 2024 Mar; 78(3):488-496. PubMed ID: 38314943
[TBL] [Abstract][Full Text] [Related]
16. Clinical Predictive Score for Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Prediabetes Using Transient Elastography.
Mahachai N; Washirasaksiri C; Ariyakunaphan P; Kositamongkol C; Sitasuwan T; Tinmanee R; Auesomwang C; Sayabovorn N; Chaisathaphol T; Phisalprapa P; Charatcharoenwitthaya P; Srivanichakorn W
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137686
[TBL] [Abstract][Full Text] [Related]
17. Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease.
Colantoni A; Bucci T; Cocomello N; Angelico F; Ettorre E; Pastori D; Lip GYH; Del Ben M; Baratta F
Cardiovasc Diabetol; 2024 May; 23(1):175. PubMed ID: 38769519
[TBL] [Abstract][Full Text] [Related]
18. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
[TBL] [Abstract][Full Text] [Related]
19. Validation of non-invasive indicators in the screening of metabolic dysfunction-associated fatty liver disease: a cross-sectional study among Uighurs in rural Xinjiang.
Guo Y; Hu Y; Yang J; Ma R; Zhang X; Guo H; Wang X; Li Y; Peng X; Zhang S; He J; Guo S
Eur J Med Res; 2023 Dec; 28(1):555. PubMed ID: 38042816
[TBL] [Abstract][Full Text] [Related]
20. Effect of CVAI on the incidence of MASLD compared to BMI in populations with different body types: A prospective cohort study in China.
Zhao Y; He Y; Zhang L; Liu J; Bai Y; Wang M; Zheng S
Nutr Metab Cardiovasc Dis; 2024 Feb; 34(2):307-316. PubMed ID: 37949714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
